Empagliflozin, Dapagliflozin And Canagliflozin Market 2026–2030: Emerging Trends and Forecast Opportunities

Uncover key drivers, emerging technologies, and competitive movements shaping the empagliflozin, dapagliflozin and canagliflozin market from 2026–2035 with trusted insights from The Business Research Company

Across 2026–2030, what is the expected market valuation path of the Empagliflozin, Dapagliflozin And Canagliflozin Market?

The empagliflozin, dapagliflozin, and canagliflozin market has shown consistent expansion in recent years. This market is projected to increase from $9.84 billion in 2025 to $10.07 billion in 2026, advancing at a compound annual growth rate (CAGR) of 2.4%. Historically, this growth can be attributed to factors such as type 2 diabetes prevalence, oral diabetes drug adoption, clinical guideline updates, cardiovascular risk awareness, and lifestyle disease growth.

The empagliflozin, dapagliflozin, and canagliflozin market size is projected to experience steady growth in the coming years, reaching $11.08 billion by 2030 at a compound annual growth rate (CAGR) of 2.4%. This anticipated growth can be attributed to factors such as the expansion of heart failure treatments, increased evidence supporting renal protection, wider adoption of diabetes combination therapy, an aging population, and a focused approach to chronic disease management. Throughout the forecast period, major trends are expected to include the rising use of SGLT-2 inhibitors in type 2 diabetes, an expansion of cardiovascular benefit indications, an increased preference for oral antidiabetic drugs, the growth of combination diabetes therapies, and a strong emphasis on long-term glycemic control.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp

Which Drivers Are Supporting The Rise Of The Empagliflozin, Dapagliflozin And Canagliflozin Market?

The rising incidence of diabetes is projected to fuel the expansion of the empagliflozin, dapagliflozin, and canagliflozin market in the future. Diabetes manifests as an ongoing medical condition characterized by elevated blood sugar levels, resulting from either insufficient insulin creation or the body’s inefficient use of insulin. This growing occurrence of diabetes is linked to elements like inactive lifestyles, poor eating patterns, genetic susceptibility, urban development, and older demographics, further complicated by restricted healthcare access and escalating global obesity figures. In diabetes treatment, empagliflozin, dapagliflozin, and canagliflozin serve to reduce blood sugar by blocking sodium-glucose co-transporter-2 (SGLT2) within the kidneys, thereby encouraging glucose elimination via urine. For example, in June 2024, data from the National Health Service (NHS), a UK government department, showed an increase among individuals younger than 40, climbing from 173,166 in 2022 to 216,440 in 2023. This substantial rise underscores an alarming pattern within this demographic. The information illustrates a swift increase in the incidence of diabetes among younger people. Consequently, the expanding occurrence of diabetes is propelling the development of the empagliflozin, dapagliflozin, and canagliflozin market.

What Segments Are Identified Within The Structure Of The Empagliflozin, Dapagliflozin And Canagliflozin Market?

The empagliflozin, dapagliflozin and canagliflozin market covered in this report is segmented –

1) By Type: Empagliflozin, Dapagliflozin, Canagliflozin

2) By Application: Type 2 Diabetes Mellitus, Heart Failure, Chronic Kidney Disease, Other Applications

3) By Channel: Hospital, Pharmacy

Subsegments:

1) By Empagliflozin: Standard Empagliflozin, Extended-Release Empagliflozin, Combination Empagliflozin Formulations, Generic Empagliflozin

2) By Dapagliflozin: Standard Dapagliflozin, Extended-Release Dapagliflozin, Combination Dapagliflozin Formulations, Generic Dapagliflozin

3) By Canagliflozin: Standard Canagliflozin, Extended-Release Canagliflozin, Combination Canagliflozin Formulations, Generic Canagliflozin

Which Trends Are Expected To Influence The Empagliflozin, Dapagliflozin And Canagliflozin Market In The Upcoming Years?

Major companies engaged in the empagliflozin, dapagliflozin, and canagliflozin markets are prioritizing the development of innovative products, including pediatric type-2 diabetes treatment, aiming to address broader patient demographics and extend their market influence in diabetes care. Pediatric Type-2 diabetes treatment involves managing blood sugar levels through lifestyle modifications, medications, and sometimes insulin therapy, specifically tailored for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 years and older with type 2 diabetes. This approval is supported by positive results from the T2NOW Phase III clinical trial, recognized as one of the most extensive pediatric type-2 diabetes trials to date, which showed that Farxiga significantly reduced HbA1c levels compared to placebo. The safety profile of Farxiga in this patient population was consistent with that observed in adults with type-2 diabetes. This approval represents an important milestone, as oral treatment options for pediatric type-2 diabetes have been limited, and it highlights AstraZeneca’s dedication to delivering innovative treatments across cardiovascular, renal, and metabolic diseases.

Which Leading Companies Dominate The Empagliflozin, Dapagliflozin And Canagliflozin Market Share?

Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are AstraZeneca PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., MSN Laboratories Private Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Johnson & Johnson, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corporation, USV Ltd., Takeda Pharmaceutical Company Limited

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/empagliflozin-dapagliflozin-and-canagliflozin-global-market-report

Which Region Is Anticipated To See The Fastest Growth In The Empagliflozin, Dapagliflozin And Canagliflozin Market?

North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2025. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Empagliflozin, Dapagliflozin And Canagliflozin Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=18350&type=smp

Browse Through More Reports Similar to the Global Empagliflozin, Dapagliflozin And Canagliflozin Market 2026, By The Business Research Company

Isoflavones Market Report 2026

https://www.thebusinessresearchcompany.com/report/isoflavones-global-market-report

Anticoagulant Market Report 2026

https://www.thebusinessresearchcompany.com/report/anticoagulant-global-market-report

Fluoxetine Market Report 2026

https://www.thebusinessresearchcompany.com/report/fluoxetine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795